Zacks Investment Research upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a research report sent to investors on Wednesday.
According to Zacks, “Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. “
MRNS has been the topic of a number of other reports. BidaskClub upgraded shares of Marinus Pharmaceuticals from a buy rating to a strong-buy rating in a report on Thursday, September 20th. Cantor Fitzgerald set a $19.00 target price on shares of Marinus Pharmaceuticals and gave the company a buy rating in a report on Tuesday, September 25th. ValuEngine lowered shares of Marinus Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, October 6th. Finally, Mizuho reaffirmed a buy rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, August 2nd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $19.67.
NASDAQ:MRNS traded down $0.26 on Wednesday, reaching $6.28. The stock had a trading volume of 782,852 shares, compared to its average volume of 857,183. The firm has a market cap of $405.25 million, a price-to-earnings ratio of -7.85 and a beta of 2.53. Marinus Pharmaceuticals has a 12-month low of $3.31 and a 12-month high of $10.54.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.09). As a group, equities analysts predict that Marinus Pharmaceuticals will post -0.73 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Trexquant Investment LP acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $102,000. GSA Capital Partners LLP acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $141,000. Rhumbline Advisers acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $245,000. Dynamic Technology Lab Private Ltd acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $363,000. Finally, Alps Advisors Inc. acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $416,000. 63.64% of the stock is owned by institutional investors.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Read More: Short Selling Stocks, A Beginner’s Guide
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.